TerminatedNot Applicable

GIST and Memory and Attention Adaptation Training

Stopped: Slow enrollment

United States2 participantsStarted 2021-01-12

Plain-language summary

Cognitive-behavioral therapy (CBT) has been found to be efficacious in the treatment of cancer-related cognitive impairment (CRCI). Memory and Attention Adaptation Training (MAAT) has been evaluated in previous clinical trials with samples of breast cancer survivors and found effective at reducing cancer-related cognitive impairment. MAAT has been demonstrated to be efficacious when it is delivered via videoconference.The use of telehealth delivery enhances access to cancer survivorship care and reduces time and travel burden among cancer survivors, especially those who live in rural and/or underserved areas where cancer survivor services are less available. People with a diagnosis of gastrointestinal stromal tumors also experience self-reported cancer-related cognitive impairment. In order to determine if MAAT can sufficiently treat CRCI among people with gastrointestinal stromal tumors (GIST), we propose a trial of MAAT to determine its initial level of effectiveness in improving both self-reported cognitive impairments and objective neuropsychological test performance in GIST patients.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age 18 and above;
. Diagnosis of Gastrointestinal stromal tumor (GIST);
. At least 1 year post-initiation of TKI therapy;
. Report cognitive problems of memory and concentration attributed to GIST and/or treatment with a score of 10 or below on the FACT-Cog Impact on Quality of Life Scale;
. Able to speak and read English;
. Able to provide IRB-approved written informed consent; and
. Willingness to use videoconferencing and complete phone-based neurocognitive assessments

Exclusion criteria

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

California Verbal Learning Test-3 (CVLT-3)

Timeframe: After 8 weekly MAAT visits (or up to 12 weeks if weekly visits are rescheduled)

Controlled Oral World Association Test (COWAT)

Timeframe: After 8 weekly MAAT visits (or up to 12 weeks if weekly visits are rescheduled)

Symbol Digit Modalities Test (SDMT)

Timeframe: After 8 weekly MAAT visits (or up to 12 weeks if weekly visits are rescheduled)

Trial details

NCT IDNCT04879979

SponsorUniversity of Pittsburgh

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05-04

View on ClinicalTrials.gov More GIST, Malignant trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age 18 and above;
. Diagnosis of Gastrointestinal stromal tumor (GIST);
. At least 1 year post-initiation of TKI therapy;
. Report cognitive problems of memory and concentration attributed to GIST and/or treatment with a score of 10 or below on the FACT-Cog Impact on Quality of Life Scale;
. Able to speak and read English;
. Able to provide IRB-approved written informed consent; and
. Willingness to use videoconferencing and complete phone-based neurocognitive assessments

Exclusion criteria

What they're measuring

California Verbal Learning Test-3 (CVLT-3)

Timeframe: After 8 weekly MAAT visits (or up to 12 weeks if weekly visits are rescheduled)

Controlled Oral World Association Test (COWAT)

Timeframe: After 8 weekly MAAT visits (or up to 12 weeks if weekly visits are rescheduled)

Symbol Digit Modalities Test (SDMT)

Timeframe: After 8 weekly MAAT visits (or up to 12 weeks if weekly visits are rescheduled)